Immunomod

Introduction

ImmunoMod is a privately held biopharmaceutical company developing and commercializing innovative therapies for the prevention and cure of diabetes and related metabolic disorders. Our platform utilizes anti-inflammatory immune-modulating molecules to attenuate auto-immune destruction. Developing an effective therapeutic to protect beta cell function in early onset Type I diabetics is our first priority and the efficacy of our lead drug candidate IM-ASN has been evidenced in animal and compassionate human studies. Active expansion of our pipeline is fueled by collaboration with the Medical University of South Carolina as well as other strategic partnerships which promote our mission.

ImmunoMod unites a revolutionary approach to diabetes therapy, the research and expertise of two prominent scientists, and the proven track record of a successful entrepreneur. Our team is unified by a common dedication to alleviate suffering caused by diabetes and other life altering diseases.

This synergistic alignment of extensive investment and entrepreneurial experience, with decades of scientific expertise in diabetes research, FDA trials, and drug development generates unprecedented impulsion behind our mission.

ImmunoMod has engaged private and public funding to carry out its efforts cure Type I diabetes.